Slide 1: Financial Results Analysis
Financial Results Analysis y Quarter ending June 30, 2011 (Q1’FY12)
Slide 2: Disclaimer
Disclaimer Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates f
Slide 3: Financial Highlights
Financial Highlights • Income from Operations of Rs 948crore, for Q1’12, up 16% YoY and 6% QoQ • Net Sales at Rs. 944crs for Q1’12, up 15% YoY and 6% QoQ • Revenue from Products at Rs 739crs grew 19% YoY and 6% QoQ • Revenue from Services Business at Rs 205crs grew 4% YoY and 7% QoQ • EBITDA at Rs.
Slide 4: Income Statement
Income Statement Particulars Q1'FY11 Q4'FY11 Q1'FY12 YoY Growth QoQ Growth (Rs Crs) (%) Net Sales 818 890 944 15% 6% Other operating Income 1 4 4 Income from Operations 819 894 948 16% 6% Total Expenditure 677 762 762 12% 0% Operating Profit 141 132 186 32% 41% Other Income 2 5 4 EBITDA including Ot
Slide 5: Revenue Analysis – Business wise
Revenue Analysis – Business wise Q1'FY11 Q4'FY11 Q1'FY12 Revenue YoY QoQ (Rs crs) Mix (%) Growth % Growth % Life Science Ingredients (LSI) 523 573 608 64% 16% 6% Generics (GX) 98 125 131 14% 33% 5% Life Science Products 621 698 739 78% 19% 6% CMO 140 133 151 16% 8% 13% DDDS 54 56 52 5% ‐5% ‐8% Other
Slide 6: Highlights – Life Science Products
Highlights – Life Science Products Life Science Products Revenue at Rs 739cr in Q1’12, contributed 78% to Net Sales • Grew 19.1% YoY with volume and positive price variance of 20.3%, negative fx impact of 1.2% • Grew 5.9% QoQ with volume and positive price variance of 6.7%, negative fx impact 0.8% 1
Slide 7: Highlights – Life Science Services
Highlights – Life Science Services Life Science Services Business Revenues at Rs205cr in Q1’FY12 • Contributed 22% share to Net Sales • Grew 4% YoY and 7% QoQ 1. CMO Services of Sterile and Non‐sterile at Rs 151crs • Contributed 16% to revenue, growing 8% YoY and 13% QoQ • Increased capacity utilisa
Slide 8: Revenue Analysis – Geography wise
Revenue Analysis – Geography wise Q1’12 Q1 12 Geo‐Mix Emerg. (Rs crs) Q1 FY11 Q4 FY11 Q1 FY12 YoY % QoQ % China Markets 8% 6% India 248 289 291 17% 1% India International 570 601 653 15% 9% Europe 31% & Japan USA & Canada 311 333 340 9% 2% 19% Europe & Japan 121 132 182 50% 38% USA & Chi China 86 71
Slide 9: Operating Expenditure Analysis
Operating Expenditure Analysis Expenses YoY QoQ Q1’FY11 % of Sales Q4’FY11 % of Sales Q1’FY12 % of Sales (Rs Crs) Growth % Growth % Material 366 45% 390 44% 418 44% 14% 7% M Manufacturing f i 66 8% 86 10% 78 8% 18% ‐9% 9% Staff 177 22% 183 21% 190 20% 7% 4% SG & A 67 8% 89 10% 73 8% 8% ‐18% Exchange
Slide 10: EBITDA Analysis
EBITDA Analysis EBITDA (Rs Crs) Q1’FY11 Q4’FY11 Q1’FY12 YoY Growth % QoQ Growth % Products 142 137 171 20% 24% Services 13 20 35 183% 80% EBITDA 155 157 206 33% 31% Corp. Allocations 11 20 16 Margins (%) Q1’FY11 Q4’FY11 Q1’FY12 bps variance bps Variance Products 22.9% 19.6% 23.1% 15 343 Services 6 3
Slide 11: Debt Profile
Debt Profile Particulars In Rs Crs % 31‐Mar‐11 30‐Jun‐11 Interest Rate Foreign Currency 847 1,782 5.1% J bil t Standalone Jubilant St d l Rupee 1509 652 11.0% FCCB 634 0 Foreign Currency 868 930 4.2% Subsidiaries Rupee 26 0 Gross Debt 3,884 3,364 6.0% Accrued Interest on FCCBs 261 0 C h & equivalent
Slide 12: Outlook
Outlook • In subsequent quarters of FY12, the Company expects to continue to build on the robust sustainable revenue and margin growth momentum recorded in the first quarter • In Products business • revenue g growth would be driven byy commissioningg of new capacities, p , innovation led product lau
Slide 13: For more information
For more information Visit us at www.jubl.com Contact us at nidhi_aggarwal@jubl.com Ph: h +91‐120 9 20 4361002 36 002 siddharth@cdr‐india.com Ph: +91‐22 6645 1209 12 12